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Dear Editor, 
 
Galantamine is a natural product belonging to the isoquinoline alkaloid family of com-
pounds. It was first discovered and isolated in the 1950s from Galanthus nivalis (common 
snowdrop) and Galanthus woronowii (Caucasian snowdrop), members of the Amaryllidaceae 
family (Marco and do Carmo Carreiras, 2006). 
Alzheimer’s disease (AD) is named after Dr. Alois Alzheimer, who first identified the dis-
ease in 1906. AD slowly destroys memory and thinking skills and is the most frequently diag-
nosed age-related neurodegenerative disorder (Prvulovic et al., 2010). Galantamine is an ace-
tylcholinesterase (AChE) inhibitor and one of the most promising drugs available for the treat-
ment of AD and various other memory impairments (Scott and Goa, 2000; Ago et al., 2011). 
Synthetic galantamine was first approved for the treatment of AD in Sweden in 2000 and was 
subsequently approved in the European Union and the United States (Heinrich and Lee Teoh, 
2004). In the present report, we reviewed the most recent studies on the pharmacological activ-
ity of galantamine (Table 1).  
 
Table 1: Recent studies on the pharmacological activity of galantamine 
Key findings Reference 
No beneficial effects of galantamine therapy were observed in patients co-treated 
with memantine 2 years post treatment. The reasons for memantine treatment 
and the possibility of interactions between memantine and galantamine merit fur-
ther investigation. 
Hager et al., 
2016 
Combination therapies using galantamine and cilostazol as well as the respective 
monotherapies maintained or even improved cognitive functions, affective func-
tions, and activities of daily living functions in AD patients with asymptomatic la-
cunar infarction. 
Hishikawa et al., 
2016 
Switching cholinesterase inhibitor (ChEI) drugs is clinically feasible for non-re-
sponding patients with mild-to-moderate AD. Inclusion of galantamine in a 
switched group was as efficacious at maintaining cognition as that observed in a 
naïve group. 
Hwang et al., 
2016 
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Key findings Reference 
The use of rod-like hydroxyapatite particles for selective delivery of galantamine 
drug and nanoceria may become an extremely powerful method for drug delivery 
to affected brain areas of patients with AD. 
Wahba et al., 
2016 
Nasal galantamine hydrobromide/chitosan complex nanoparticles have been 
shown to be pharmacologically efficacious. Further, their safety has been demon-
strated in vivo, confirming their potential to contribute to the intranasal manage-
ment of AD. 
Hanafy et al., 
2016 
Galantamine enhances striatal dopamine release through allosteric modulation of 
α4 nicotinic acetylcholine receptors on nigrostriatal dopaminergic terminals. Inden et al., 2016
Donepezil, tacrine, galantamine, and rivastigmine are known to cause convul-
sions and have anticholinesterase effects. Further, they have been shown to de-
crease locomotion in an invertebrate model. 
Bezerra et al., 
2016 
The bioavailability of galantamine hydrobromide-loaded solid-lipid nanoparticles 
is twice that of galantamine hydrobromide alone. Thus, these nanoparticle carri-
ers show promise for safe and effective drug delivery, especially in diseases such 
as AD. 
Misra et al., 2016 
Galantamine therapy, unlike donepezil, is characterized by a dual mechanism of 
action that may increase acetylcholine and the nicotinic receptor-modulation ef-
fect within the frontal lobe, both of which are associated with apathy and execu-
tive dysfunction in AD patients. 
Oka et al., 2016 
Benefits to cognitive and affective functions were greater in AD patients receiving 
the combination therapy of galantamine plus ambulatory cognitive rehabilitation 
than in those receiving galantamine therapy only.  
Tokuchi et al., 
2016 
Galantamine may be involved in modifying AD pathophysiological mechanisms 
by alleviating amyloid-β deposition and neuroinflammation. The results from this 
study provide new evidence for the use of galantamine in the treatment of AD. 
Wu et al., 2015 
This is a long-term study examining the efficacy of galantamine in very elderly AD 
patients, suggesting improved efficacy in male patients and baseline lower cogni-
tive, affective, and activity of daily living functions. 
Nakano et al., 
2015 
A galantamine derivative is emerging as a promising lead compound for multi-tar-
get anti-AD therapy because of its strong inhibitory activity and ability to block 
amyloid beta deposition on acetylcholinesterase. 
Atanasova et al., 
2015 
Novel galantamine-loaded polymeric nanoparticles have been designed for the 
first time using a nano-emulsification approach. This study demonstrates the ap-
propriate features required for advanced drug delivery systems to treat neuro-
degenerative diseases. 
Fornaguera et 
al., 2015 
The patch system (galantamine hydrobromide loaded gel drug reservoirs in 
transdermal patches) has moderate pH, high drug content, and a controlled drug-
release pattern. Thus, the patch system has the potential to be used as a drug 
carrier system for the treatment of AD.  
Woo et al., 2015 
Memogain, a pro-drug, releases galantamine in the brain by cleavage with a car-
boxyesterase. Nasal applications of memogain effectively deliver the drug to the 
brain of AD patients with the potential to retard plaque deposition and improve 
behavioral symptoms like those observed with galantamine treatment. 
Bhattacharya et 
al., 2015 
 
Galantamine significantly improves cognitive, behavioral, and global performance 
in patients with AD. However, it needs to be used with caution in clinical settings. Jiang et al., 2015 
Patients with mild cognitive impairment treated with galantamine had a lower rate 
of whole brain atrophy, but not hippocampal atrophy, over a 24-month treatment 
period than patients who were treated with placebo. However, the protective ef-
fect of galantamine on the rate of whole brain atrophy in MCI was only observed 
in apolipoprotein E ϵ4 carriers. 
Prins et al., 2014 
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Key findings Reference 
Soman is a nerve agent that reduces hippocampal glutamatergic synaptic trans-
mission and may result in cognitive deficits long after an acute exposure. Preven-
tion of soman-induced reductions in hippocampal glutamatergic synaptic trans-
mission may be an important determinant of galantamine’s ability to counter the 
related cognitive deficits.  
Alexandrova et 
al., 2014 
Pre-treatment with galantamine in a newborn rat model of hypoxia-ischemia re-
duced brain damage with a suppressive effect on microglial accumulation and in-
terleukin-1 beta production. 
Furukawa et al., 
2014 
In addition to its previously known cognitive benefits, galantamine treatment im-
proved quality of life in mixed dementia patients; however, the combination of 
galantamine and nimodipine was not advantageous. The small sample size of 
this study precludes any definitive conclusions. 
Caramelli et al., 
2014 
The combination of galantamine and memantine may be more effective at in-
creasing selective cognition in schizophrenia patients than either medication 
alone. In the future, multitarget-directed ligands may play a role in the treatment 
of complex diseases like schizophrenia. 
Koola et al., 2014
Galantamine promotes neurogenesis by activating the M1 muscarinic and α7 nic-
otinic acetylcholine receptors. This study suggests that insulin-like growth factor 2 
is also involved in the effects of galantamine on survival of 2-wk-old immature 
cells in the granule cell layer. 
Kita et al., 2014 
Long-term treatment with galantamine significantly reduced mortality and declin-
ing cognition and daily living activities in mild to moderate AD patients.
Hager et al., 
2014 
In addition to improving cognitive and behavioral symptoms in AD, galantamine 
may have disease-modifying and neuroprotective properties, as indicated by de-
layed amyloid β plaque formation and reduced gliosis.  
Bhattacharya et 
al., 2014 
Cognition, behavior, and activities of daily living improved during 12 months of 
galantamine treatment. At the 3-year follow-up, a decline in all outcomes was 
measured; however, cognition remained higher in the treated group than that in 
an untreated group. 
Richarz et al., 
2014 
This study examined the galantamine-associated reversal of scopolamine-in-
duced learning and memory impairments.  
Ramakrishnan et 
al., 2014 
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